losartan has been researched along with Blood Poisoning in 5 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
| Excerpt | Relevance | Reference |
|---|---|---|
| "We hypothesized that angiotensin II, a potent vasoconstrictor, is involved in the occurrence of hepatic ischemia after burn and sepsis, and that administration of angiotensin II antagonist DuP753 would ameliorate this process." | 7.70 | Trauma- and sepsis-induced hepatic ischemia and reperfusion injury: role of angiotensin II. ( Herndon, DN; Tadros, T; Traber, DL, 2000) |
| "Losartan treatment significantly attenuated TNF-alpha, IL-6, and IL-1beta 6 h after CLP." | 5.35 | Losartan prevents sepsis-induced acute lung injury and decreases activation of nuclear factor kappaB and mitogen-activated protein kinases. ( Cai, L; Kong, T; Mo, H; Qi, J; Shen, L; Xiao, Z; Ye, J; Zheng, W, 2009) |
| "We hypothesized that angiotensin II, a potent vasoconstrictor, is involved in the occurrence of hepatic ischemia after burn and sepsis, and that administration of angiotensin II antagonist DuP753 would ameliorate this process." | 3.70 | Trauma- and sepsis-induced hepatic ischemia and reperfusion injury: role of angiotensin II. ( Herndon, DN; Tadros, T; Traber, DL, 2000) |
| "Losartan treatment significantly attenuated TNF-alpha, IL-6, and IL-1beta 6 h after CLP." | 1.35 | Losartan prevents sepsis-induced acute lung injury and decreases activation of nuclear factor kappaB and mitogen-activated protein kinases. ( Cai, L; Kong, T; Mo, H; Qi, J; Shen, L; Xiao, Z; Ye, J; Zheng, W, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, XS | 1 |
| Wang, SH | 1 |
| Liu, CY | 1 |
| Gao, YL | 1 |
| Meng, XL | 1 |
| Wei, W | 1 |
| Shou, ST | 1 |
| Liu, YC | 1 |
| Chai, YF | 1 |
| Leisman, DE | 1 |
| Fernandes, TD | 1 |
| Bijol, V | 1 |
| Abraham, MN | 1 |
| Lehman, JR | 1 |
| Taylor, MD | 1 |
| Capone, C | 1 |
| Yaipan, O | 1 |
| Bellomo, R | 1 |
| Deutschman, CS | 1 |
| Shen, L | 1 |
| Mo, H | 1 |
| Cai, L | 1 |
| Kong, T | 1 |
| Zheng, W | 1 |
| Ye, J | 1 |
| Qi, J | 1 |
| Xiao, Z | 1 |
| Yasuda, S | 1 |
| Lew, WY | 1 |
| Tadros, T | 1 |
| Traber, DL | 1 |
| Herndon, DN | 1 |
5 other studies available for losartan and Blood Poisoning
| Article | Year |
|---|---|
Losartan attenuates sepsis-induced cardiomyopathy by regulating macrophage polarization via TLR4-mediated NF-κB and MAPK signaling.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotens | 2022 |
Impaired angiotensin II type 1 receptor signaling contributes to sepsis-induced acute kidney injury.
Topics: Acute Kidney Injury; Angiotensin II; Animals; Case-Control Studies; Humans; Losartan; Mice; Receptor | 2021 |
Losartan prevents sepsis-induced acute lung injury and decreases activation of nuclear factor kappaB and mitogen-activated protein kinases.
Topics: Acute Lung Injury; Angiotensin II Type 1 Receptor Blockers; Animals; Blotting, Western; Interleukin- | 2009 |
Angiotensin II exacerbates lipopolysaccharide-induced contractile depression in rabbit cardiac myocytes.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Calcium; Cells, Cultured; Chelating Agents; Cyclic | 1999 |
Trauma- and sepsis-induced hepatic ischemia and reperfusion injury: role of angiotensin II.
Topics: Analysis of Variance; Angiotensin II; Animals; Burns; Drug Evaluation, Preclinical; Escherichia coli | 2000 |